In patients with COPD and atrial fibrillation or flutter, vitamin K antagonists carry a lower 1‑year risk for hospitalization ...

Do vitamin K antagonists affect COPD outcomes? New cohort data explore exacerbation and mortality risk compared with DOACs.

U.S. adults faced a greater likelihood for COPD if their daily sugar caloric intake from sugar-sweetened beverages was 10% or ...

Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...

Your patients with chronic obstructive pulmonary disease (COPD) may need help not just coping with their condition but also managing it in their workplace. The symptoms of COPD, a lung and airway ...

A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the ...

Novel, experimental treatment for emphysema may offer promising results for patients looking to breathe easier ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab and mepolizumab are the only FDA-approved biologics for adults with COPD and an eosinophilic phenotype ...

GSK's Nucala (mepolizumab) has received European Commission approval as an add on maintenance treatment for uncontrolled COPD. The approval is supported by positive Phase III MATINEE trial results.

GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...